Form 4: Pfizer Executive Aamir Malik Acquires Stock Appreciation Rights

Executive Vice President Aamir Malik acquired stock appreciation rights (SARs) tied to Pfizer common stock, according to a Form 4 filing with the SEC.

Summary

• A Form 4 filing with the SEC indicates that Aamir Malik, an Executive Vice President at Pfizer, acquired stock appreciation rights (SARs).
• The SARs are linked to Pfizer common stock and were granted on February 27, 2024.
• Malik acquired 161,160 SARs that will be settled in shares of Pfizer common stock on February 27, 2029, the fifth anniversary of the grant date.
• He also acquired 142,400 SARs that will be settled in shares of Pfizer common stock on February 27, 2031, the seventh anniversary of the grant date.
• The exercise price for both sets of SARs is $26.89.
• Following the reported transactions, Malik directly owns 161,160 and 142,400 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive compensation. The acquisition of SARs could be interpreted as a positive sign of the executive's confidence in the company, but it's not a strong indicator.

Positives

• The acquisition of SARs by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding Pfizer's future performance, but the acquisition of SARs by an executive suggests an expectation of future stock price appreciation.

Industry Context

Executive compensation packages often include stock-based awards like SARs to align management's interests with those of shareholders. This filing is a routine disclosure of such an award.

Comparison to Industry Standards

• Stock appreciation rights are a common form of equity compensation used by large pharmaceutical companies like Pfizer to incentivize executives.
• Companies such as Johnson & Johnson, Merck, and AbbVie also utilize similar equity-based compensation strategies.
• The vesting schedules and exercise prices are generally aligned with industry norms for executive compensation.

Stakeholder Impact

• The acquisition of SARs by a Pfizer executive could have a minor positive impact on shareholder sentiment, as it suggests confidence in the company's future performance.
• The compensation structure impacts employees by aligning executive incentives with company performance.

Key Dates